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Abstract
MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs that are negative regulators in a crescent number of
physiological and pathological processes. However, their role in haemostasis, a complex physiological process involving
multitude of effectors, is just beginning to be characterized. We evaluated the changes of expression of miRNAs in livers of
neonates (day one after birth) and adult mice by microarray and qRT-PCR trying to identify miRNAs that potentially may also
be involved in the control of the dramatic change of hepatic haemostatic protein levels associated with this transition.
Twenty one out of 41 miRNAs overexpressed in neonate mice have hepatic haemostatic mRNA as potential targets. Six of
them identified by two in silico algorithms potentially bind the 39UTR regions of F7, F9, F12, FXIIIB, PLG and SERPINC1 mRNA.
Interestingly, miR-18a and miR-19b, overexpressed 5.4 and 8.2-fold respectively in neonates, have antithrombin, a key anti-
coagulant with strong anti-angiogenic and anti-inflammatory roles, as a potential target. The levels of these two miRNAs
inversely correlated with antithrombin mRNA levels during development (miR-19b: R=0.81; p=0.03; miR-18a: R=0.91;
p,0.001). These data suggest that miRNAs could be potential modulators of the haemostatic system involved in
developmental haemostasis.
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Introduction
MicroRNAs (miRNAs) are an abundant class of small non-
coding RNAs of ,22 nucleotides in length that function as
negative gene regulators [1,2]. In animals, miRNAs are involved
in processes such as tissue development and cell differentiation [3],
apoptosis [4], in which fine regulation of gene expression in time
and space is required for the correct execution of these processes;
and in diseases such as cancer [5]. These known functions may
represent just a small part of a much bigger scenario; the main
known function of miRNAs is the regulation of gene expression at
the post-transcriptional level either by protein translation inhibi-
tion or mRNA decay [6,7]. One third of the genes in the human
genome are predicted to be miRNAs targets [8] and the
continuing discovery of new miRNAs functions suggest that these
molecules are implicated in the regulation of almost every
physiological processes. Profile studies have already shown that
many miRNAs are specifically expressed in certain organs, cell
types and developmental stages [3].
To date only two recent studies have demonstrated that key
haemostatic proteins, PAI-1 and fibrinogen, may be regulated by
miRNA [9,10], probably just reflecting the tip of the iceberg
concerning regulation of haemostasis by miRNA. In this study, we
tried to show the potential relevance that miRNAs regulation
might have in the whole haemostatic system, by evaluating the
differential expression of miRNAs in the liver of mice associated
with the extraordinary change in the expression of hepatic
haemostatic proteins after birth. Developmental haemostasis refers
to the age-related changes in the coagulation system that are most
marked during neonatal life and childhood [11]. Actually, the
haemostatic system is incompletely developed at birth and matures
throughout infancy. Neonates have low levels of the most
procoagulant and anticoagulant proteins, although the levels of
the factors V, VIII, XIII, and fibrinogen in neonates are similar to
adult [12]. The most intriguing aspect of developmental
haemostasis is to understand the mechanisms and rationale for
such marked age-related changes. Previous studies have confirmed
that post-translational modifications in coagulation proteins do
occur with age. Moreover, significant differences at the transcrip-
tional levels can also contribute to these differences. However, due
to the role of miRNAs in development, these molecules may also
contribute directly or indirectly to the dramatic changes in the
haemostatic system observed in neonates [2,12].
Results
We studied the differential expression pattern of 558 mature
miRNAs in liver from an adult and a neonate mouse. As expected,
we found that miRNAs expression profiles significantly differed in
these two stages. The expression level of 81 miRNAs significantly
changed between livers from adult and neonate (Figure 1). We
filtered these data by the fold change, and found that 68 out of 81
miRNAs showed at least a two-fold expression change between
neonate and adult liver (Table 1). Among these miRNAs, 41 were
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17648Figure 1. miRNA expression profile. Differentially expressed miRNAs were clustered by Cluster3.0. Log2 scale was employed. In red miRNAs
overexpressed in neonate liver; in green miRNAs overexpressed in adult liver.
doi:10.1371/journal.pone.0017648.g001
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miRNAs were overexpressed in adult when compared to neonate
(Table 1). If certain miRNAs were directly involved in the control
of the expression of haemostatic proteins, we could find such
candidates among the miRNA overexpressed in neonates. Thus,
we performed an exhaustive in silico search of haemostatic proteins
that might be potential targets of the 41 miRNAs overexpressed in
neonate mice. Interestingly, 21 out of 41 miRNAs overexpressed
in neonate mice, have haemostatic mRNA as potential targets
(Table 2). When we focused on those targets predicted by both
algorithms, we found 6 miRNA that potentially can bind the
39UTR regions of mRNA from F7 (encoding the coagulation
factor VII), F9 (encoding the coagulation factor IX), F12 (encoding
the coagulation factor XII), FXIIIB (encoding the coagulation
factor XIII, B polypeptide), PLG (encoding plasminogen), and
SERPINC1 (encoding the anticoagulant antithrombin) genes. All
these proteins are significantly lower in neonates compared with
adults in humans although no data are available in mice. Then we
validated the expression of these miRNA observed in the
microarray in 14 neonate mice (+1 day after bird) and 6 adult
mice by qRT-PCR. The results obtained were fully comparable,
and the relative fold changes of miRNA expression were similar to
those detected by microarrays (r=0.78, p,0.05) (Figure 2). We
were particularly interested to deepen in two miRNAs: miR-18a
and miR-19b which are overexpressed 5.4 and 8.2-fold and both
have antithrombin as a potential target. Antithrombin is a key
anticoagulant that also plays other relevant roles outside the
haemostatic system such as strong anti-angiogenic [13] and anti-
Table 1. Potential haemostatic factor mRNA targeted by miRNAs overexpressed in neonate liver.
miRNA Fold change mirGen Targetscan
mmu-miR-376b 85,6 - Protein C, Factor V
mmu-miR-154 26,5 - Factor IX
mmu-miR-379 26,9 Factor VIII Factor V
mmu-miR-223 15,1 Factor IX
#, plasminogen
# Factor VIII, Factor IX
#, Plasminogen
#
mmu-miR-495 14,3 Factor II -
mmu-miR-382 17,9 Factor XIII (beta subunit), Plasminogen -
mmu-miR-200a 8,4 Factor XIII (beta subunit) -
mmu-miR-130b 7,5 Antithrombin, Factor XIII (beta subunit) Protein C
mmu-miR-19b 8,2 Antithrombin
#, Factor XIII (beta subunit) Antithrombin
#
mmu-miR-300 9,2 Factor XIII (beta subunit)
# Factor XIII (beta subunit)
#
mmu-miR-134 8,2 Factor VII
# Factor VII
#
mmu-miR-299* 9,0 Factor II, Factor XI -
mmu-miR-199a-5p 4,3 - Factor XI, Factor XII
mmu-miR-18a 5,4 Antithrombin
# Antithrombin
#
mmu-miR-667 5,2 Protein S (alpha), Factor VII -
mmu-miR-99b 4,0 Plasminogen, Factor II -
mmu-miR-30e 2,3 - Factor XI
mmu-miR-145 2,8 Plasminogen -
mmu-miR-30a 2,5 - Factor XI
mmu-miR-130a 2,0 Antithrombin, Factor XIII (beta subunit) Protein C
mmu-miR-181a 2,4 Factor VII, Factor X, Factor XII
#, Protein S (alpha) Factor XII
#, FactorXI
#mRNA targeted in both algorithms.
doi:10.1371/journal.pone.0017648.t001
Table 2. Potential haemostatic factor mRNA targeted by miRNAs over-expressed in neonate liver.
miRNA mirGen Targetscan
"mmu-miR-223 Factor IX*, Plasminogen* Factor VIII, Factor IX*, Plasminogen*
"mmu-miR-19b Antithrombin*, Factor XIII (beta subunit) Antithrombin*
"mmu-miR-300 Factor XIII (beta subunit)* Factor XIII (beta subunit)*
"mmu-miR-134 Factor VII* Factor VII*
"mmu-miR-18a Antithrombin* Antithrombin*
#mmu-miR-181a Factor VII, Factor X, Factor XII*, Protein S (alpha) Factor XI, Factor XII*
"Overexpressed 4–32-fold in comparison with adult liver,
#overexpressed 2–4-fold in comparison with adult liver.
*mRNA targeted in both algorithms.
doi:10.1371/journal.pone.0017648.t002
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naturally reduced in newborns to less than 50% of the levels
observed in adults and then increase to approach adult levels by
approximately six months of age in humans [15]. First, we
confirmed the lower antigenic levels of antithrombin in plasma of
neonate mice compared with adults (3464 vs. 8667, respectively),
reaching adult levels at +13 days after birth. Interestingly, when
quantifying miR-18a, miR-19b, and antithrombin mRNA during
the 19 days after birth, we found an inverse and significant
correlation (miR-19b: R=0.81; p=0.03; miR-18a: R=0.91;
p,0.001) (Figure 3). We point out that miR-18a and miR-19b
are also expressed in human liver where their expression pattern
during development is similar to that observed in our study [16].
Discussion
Our study has identified 41 miRNAs overexpressed in livers of
neonate mice, some of them with potential direct effect on hepatic
haemostatic proteins that dramatically change their levels after
birth. The inverse correlation observed between miR-18a and
miR-19b levels with antithrombin mRNA, one potential target of
these miRNAs, suggests that certain miRNAs may be involved in
the regulation of selected hepatic haemostatic proteins during
development by targeting mRNA coding for these proteins and be
in part responsible of the observed decay in neonates [12]. Indeed,
Tzur et al. suggested that in humans several biological processes
and pathways, in particular blood coagulation, may be regulated
during the embryonic period by differentially expressed miRNAs
[16]. Beside the potential role of miRNAs in the regulation of
haemostatic proteins in developmental haemostasis in liver, these
molecules may also be of relevance in adults where the wide inter-
individual variability for haemostatic proteins may be potentially
responsible of bleeding or thrombotic disorders. In addition,
miRNAs may also play a role through indirect mechanisms, by
regulating transcriptional factors or post-translational modifica-
tions affecting haemostatic elements. Several studies have shown
that certain miRNAs may regulate the levels of transcription
factors expressed in the liver, potentially involved in the regulation
of the transcription of a large panel of hepatic haemostatic
mRNAs [17,18,19]. Additionally, our results are based on a
microarray performed on the expression of 558 miRNAs, the use
of novel miRNA databases would certainly add additional miRNA
candidates as potential regulators of other hepatic haemostatic
proteins not described in our study. Obviously, the main limitation
of our study is that it did not demonstrate through in vitro
experiments the validity of our hypothesis. To note, we looked for
a cellular model that endogenously express antithrombin in order
to inhibit its expression with oligonucleotide precursors. First, we
examined AML12, a murine hepatocyte cell line that unexpect-
edly, did not express antithrombin. We next move to NIH3T3
cells that do express antithrombin and we performed transfection
assays with oligonucleotide precursors and inhibitors (pre-miRs
and antagomiRs from Applied Biosystems, Madrid, Spain) of miR-
18a and miR-19b to evaluate their effect in the expression of
antithrombin. Our results suggest that these miRNAs might not
have a direct effect on antithrombin levels in this cell line (data not
shown). However, this cellular model had several pitfalls.
Particularly, NIH3T3 cells are not a hepatic cell line, and
accordingly, cytosolic environment may be completely different
from that of hepatocytes. Moreover, the level of expression of
antithrombin is very low, and fibroblasts do not express
antithrombin in the adulthood. Further studies are required to
sustain the potential role of miRNA in the dramatic change of the
haemostatic system after birth. Thus, it is necessary to clarify the
mechanisms of action of candidate miRNA overexpressed in
neonates on the levels of haemostatic proteins. Any potential direct
inhibitory effect of miRNAs must be demonstrated under
appropriate conditions: i.e. embryonic mouse hepatocytes trans-
fected with miRNA inhibitors or adult mouse hepatocytes
transfected with miRNA oligonucleotide precursors. On the other
hand, the indirect effect of miRNA on haemostatic protein
regulation by targeting transcription factors may also be extremely
relevant to evaluate.
In conclusion, these results open new fascinating perspectives in
thrombosis and haemostasis by introducing novel elements,
miRNAs, as potential regulators of the haemostatic system.
Methods
Mouse samples
For microarray assay, we sacrificed one mice of different stage
of development: one day after birth mouse (neonate) and fifty days
after birth mouse (adult). On the other hand, we used 6 adult mice
and 14 neonate mice from at 4 different litters, which did not
include the samples used for the microarray assays, to perform
miRNA expression validation assay. Finally, we sacrificed 3 mice
from different litters, from neonate stage (day +1) to adult stage
(day +50) each two days, to perform the quantification of
antithrombin mRNA levels and miRNAs miR-18a and miR-19b
levels, during post-natal development. In all case we used swiss
Figure 2. miRNA expression validation. (A) Selected miRNAs were
validated by RT-PCR using specific assays. (B) Correlation between data
from microarray and RT-PCR for selected miRNAs was performed using
lineal regression (SPSS15.0 software). P,0.05 was considered as
statistically significant.
doi:10.1371/journal.pone.0017648.g002
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TM) mice. Livers were finely dissected and immediately
frozen in liquid nitrogen and kept at 280uC until their use. Blood
was anticoagulated with citrate and plasma stored at 280uC.
All experimental procedures were performed in accordance
with the approved Institutional Animal Care Guidelines from the
University of Murcia. The study was approved by the Ethics
Committee from Fundacio ´n para la Formacio ´n e Investigacio ´n
Sanitarias de la Regio ´n de Murcia (04–23/2008).
RNA Isolation
Total RNA was isolated from frozen liver using TrizolH
Reagent (Invitrogen, Carlsbad, CA) following manufacturer’s
instructions. The RNA concentration and 260/280 ratio were
determined by using NanoDrop spectrophotometer (Thermo
Scientific, Wilmington, DE) and RNA integrity was verified by
lab-on-chip technology using the Experion automated electropho-
resis system (Bio-Rad Laboratories, Madrid, Spain).
MicroRNA microarray
MicroRNAs microarray profiling was performed using total
RNA extracted from the liver from one adult mouse (day +50) and
one neonate mouse (day +1) using the LC Sciences technology (LC
Sciences, Houston, TX). The arrays were designed to detect and
quantify miRNA transcripts corresponding to 558 mature
miRNAs contained in the Sanger mirBase Release 10.0 (miR-
Mouse 10.0) http://www.sanger.ac.uk/Software/Rfam/mirna/.
Figure 3. Expression of antithrombin and miRNAs miR-18a and miR-19b during post-natal development in mouse. (A) miRNAs and
antithrombin mRNA were measured in liver from mice during postnatal development using cDNA specific assays. RT-PCR was performed in three
mice from each age. Data are shown as relative level (% 6 SD) taking adults as reference for antithrombin mRNA and +1 day neonates for miRNAs. (B)
Expression correlation between miR-19b and miR-20a levels with AT mRNA levels, during post-natal development.
doi:10.1371/journal.pone.0017648.g003
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either with cy3 or with cy5. The signal values were derived by
background subtraction and normalization. A transcript to be
listed as detectable must meet at least two conditions: signal
intensity higher than 36(background SD) and spot CV,0.5. CV
is calculated by (SD)/(signal intensity). When repeating probes
were present on an array, a transcript was listed as detectable only
if the signals from at least 50% of the repeating probes were above
detection level. Signals were listed in median signal values of
repeating probes of p-value,0.01. Median values were used to
minimize the effect of occasional ‘‘non-uniform spots’’ that may
have signal values deviate from average signal values but have p-
values,0.01.
All differentially expressed transcripts with p-value,0.01, were
presented in log2 scale, positive log2 value indicates an upper
regulation and a negative log2 value indicates a down regulation.
Validation by qRT-PCR
The RT reaction was performed using 200 ng of total RNA for
each sample according to the manufacturer instructions (Super-
Script First Strand, Invitrogen, Madrid, Spain). The Real Time
reactions were performed using Taqman Gene Expression Assay
on a LC480 Real Time PCR (Roche, Madrid, Spain). For mature
miRNA quantification one set of primers and a probe were chosen
from Applied Biosystems. Expression analysis was performed in
triplicates for each sample. Expression of U6 snRNA was used as
endogenous reference control. The fold difference for each sample
was obtained using the 2
2DDCt method.
Target analysis
In silico search of potential miRNA targets was performed in the
following miRNA-target prediction algorithms : TargetScan
(release 5.1, http://www.targetscan.org) [8], mirGen (http://
www.diana.pcbi.upenn.edu/miRGen) [20].
Statistical analysis
Lineal regression was performed by Statistical Package for
Social Science (version 15.0; SPSS, Chicago, IL, USA). Data are
presented as mean 6 standard deviation. Statistical significance
was taken as P,0.05.
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